Comparison of the prognostic utility of the revised International Prognostic Scoring System and the <scp>F</scp>rench Prognostic Scoring System in azacitidine‐treated patients with myelodysplastic syndromes

SummaryThe revised International Prognostic Scoring System (IPSS‐R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine‐treated patients with high‐risk MDS. We applied the FPSS and IPSS‐R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS‐R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS‐R in azacitidine‐treated patients.